Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This is a randomized, double-blind (60 -79 years) and open-label (40-59 years), three-arm parallel Phase 3b, multicenter study to evaluate the safety and non-inferiority of the humoral immune response of the Butantan Dengue vaccine (Dengue 1,2,3,4 (attenuated)) in participants aged 60 -79 years (elderly) compared to participants aged 40 to 59 years (adults), with or without previous dengue and healthy based on clinical examination.
Epistemonikos ID: 8f0a161661b821ec3a8cda1fc55454c8aa37769a
First added on: Mar 26, 2025